News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

BioProcessors Corp.’s SimCell(TM) Platform Selected By Novo Nordisk A/S (NVO)


10/19/2005 5:12:11 PM

WOBURN, MA, U.S.A. September 13, 2005. BioProcessors announced the sale of the SimCell (TM) MicroBioreactor Automation Management System to Novo Nordisk A/S (NYSE: NVO), having successfully completed platform evaluation trials. The SimCell (TM) platform enables Novo Nordisk to rapidly accelerate their mammalian cell culture process development initiatives. As a result of the joint effort, the companies demonstrated the predictability and scalability of BioProcessors’ MicroBioreactor Array and a high-throughput robotic workstation to conventional bioreactor systems. BioProcessors’ SimCell MicroBioreactor solutions enable biotechnology and pharmaceutical companies to increase cell culture experiment capacity by orders-of-magnitude with greater data quality, faster cycles and lower costs than conventional biopharmaceutical processing methods.



comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES